Acadia Pharmaceuticals Inc. (ACAD) Q3 2009 Earnings Results

ACADIA PHARMACEUTICA Beats on EPS, Stock Up 4.51%

The earnings report shows that ACADIA Pharmaceuticals managed to beat EPS expectations, which contributed to a positive stock reaction, with shares rising by 4.51%. Investors may be encouraged by the company's commitment to advancing its pipeline, even though no revenue figures or guidance were disclosed. The market's reaction suggests that investors are optimistic about the company's future potential despite the lack of detailed financial metrics.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	-$0.23	N/A	+13.21%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on their development programs and is optimistic about future prospects. However, they did not provide specific guidance for upcoming quarters.

Management highlighted ongoing efforts to advance their pipeline.

They expressed confidence in their strategic direction despite the lack of revenue guidance.

ACADIA PHARMACEUTICA Beats on EPS, Stock Up 4.51%

Key numbers

Management commentary

Acadia Pharmaceuticals Inc.

More earnings this week

ACADIA PHARMACEUTICA Beats on EPS, Stock Up 4.51%

Key numbers

Management commentary